We are live on
!
Find out more
BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM
$372M
1-Year Est. Return
78.25%
This Fund
S&P 500
This Quarter
Est. Return
+5.38%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$289M
(+224%)
Cap. Flow
+$359M
Cap. Flow
% of AUM
85.74%
Top 10 Holdings %
Top 10 Hldgs %
73.32%
Holding
45
New
30
Increased
2
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Toast
TOST
|
+$91.3M |
| 2 |
Pliant Therapeutics
PLRX
|
+$45.7M |
| 3 |
Cullinan Oncology
CGEM
|
+$30.3M |
| 4 |
TRML
Tourmaline Bio
TRML
|
+$26.7M |
| 5 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$25.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starwood Property Trust
STWD
|
+$2.13M |
| 2 |
GitLab
GTLB
|
+$1.2M |
| 3 |
FATH
Fathom Digital Manufacturing Corporation
FATH
|
+$217K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.67% |
| 2 | Financials | 20.39% |
| 3 | Technology | 11.87% |
| 4 | Industrials | 0.19% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pliant Therapeutics
PLRX
$65M
| $54.4M | 13.01% |
+3,004,199
| New | +$45.7M |
|
2
Robinhood
HOOD
$80.7B
| $54M | 12.9% |
4,237,409
| – | – |
|
|
3
Cullinan Oncology
CGEM
$1.06B
| $34.8M | 8.33% |
+3,419,842
| New | +$30.3M |
|
|
TRML
4
DELISTED
Tourmaline Bio
TRML
| $32.4M | 7.74% |
+1,332,302
| New | +$26.7M |
|
5
Klaviyo
KVYO
$5.8B
| $31.5M | 7.52% |
1,198,270
| – | – |
|
6
Blue Owl Capital
OBDC
$5.35B
| $30.2M | 7.22% |
2,045,070
| – | – |
|
|
RPTX
7
DELISTED
Repare Therapeutics
RPTX
| $22.8M | 5.45% |
+3,122,499
| New | +$17.5M |
|
|
SLRN
8
DELISTED
ACELYRIN
SLRN
| $17.1M | 4.09% |
+2,292,990
| New | +$19.6M |
|
9
Larimar Therapeutics
LRMR
$377M
| $15.5M | 3.71% |
+3,414,468
| New | +$11.5M |
|
10
Keros Therapeutics
KROS
$197M
| $14M | 3.35% |
+352,633
| New | +$11.1M |
|
11
Ultragenyx Pharmaceutical
RARE
$2.46B
| $12.6M | 3.01% |
+263,238
| New | +$10.2M |
|
12
enGene Therapeutics
ENGN
$120M
| $11.4M | 2.72% |
+1,234,760
| New | +$10.9M |
|
|
SYRS
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $8.46M | 2.02% |
+1,493,252
| New | +$5.11M |
|
14
Disc Medicine
IRON
$2.81B
| $8.1M | 1.94% |
+140,260
| New | +$7.18M |
|
|
ETWO
15
DELISTED
E2open Parent Holdings
ETWO
| $7.25M | 1.73% |
1,650,943
| – | – |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $6.63M | 1.59% |
+71,888
| New | +$4.66M |
|
|
17
Toast
TOST
$18.9B
| $6.04M | 1.44% |
5,890,274
+5,567,696
| +1,726% | +$91.3M |
|
|
INZY
18
DELISTED
Inozyme Pharma
INZY
| $5.41M | 1.29% |
+1,270,027
| New | +$4.51M |
|
19
Mineralys Therapeutics
MLYS
$2.32B
| $4.89M | 1.17% |
+568,379
| New | +$4.46M |
|
20
Compass Therapeutics
CMPX
$349M
| $4.41M | 1.06% |
+2,829,712
| New | +$4.9M |
|
21
MoonLake Immunotherapeutics
MLTX
$1.56B
| $3.93M | 0.94% |
+65,000
| New | +$3.35M |
|
|
IMA
22
ImageneBio Inc
IMA
$63.4M
| $3.85M | 0.92% |
+162,801
| New | +$5.31M |
|
23
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$70.3M
| $3.29M | 0.79% |
+34,000
| New | +$6.62M |
|
|
OMGA
24
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $3.18M | 0.76% |
+1,055,882
| New | +$2.14M |
|
25
Ovid Therapeutics
OVID
$427M
| $2.78M | 0.67% |
+864,822
| New | +$2.96M |
|
Similar funds
PC
GIP
DPCM
SAAM
MWM
AWA
KP
TCM
Blue Owl Capital Holdings's Q4 2023 Portfolio in Review
As of Q4 2023, Blue Owl Capital Holdings held 45 positions worth $418M, up 224% from $129M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Blue Owl Capital Holdings deployed $359M of net new capital in Q4 2023, opening 30 new positions and adding to 2 existing holdings. Its largest new stake was Pliant Therapeutics: 3,004,199 shares worth $54.4M.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 0.62% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Fathom Digital Manufacturing Corporation, an estimated $217K trimmed.
- Blue Owl Capital Holdings's largest Q4 2023 buy was Pliant Therapeutics: 3,004,199 shares worth $54.4M.
- Blue Owl Capital Holdings added most to Toast in Q4 2023, an estimated $91.3M increase.
- Blue Owl Capital Holdings's biggest Q4 2023 reduction was Fathom Digital Manufacturing Corporation, cutting an estimated $217K.
- Blue Owl Capital Holdings fully exited Starwood Property Trust in Q4 2023, selling an estimated $2.13M.
- Blue Owl Capital Holdings's ten largest holdings make up 73% of its $418M portfolio in Q4 2023.
- Blue Owl Capital Holdings opened 30 new positions and closed 2 in Q4 2023.
- Blue Owl Capital Holdings's portfolio value rose 224% quarter-over-quarter to $418M.
Based on Blue Owl Capital Holdings's 13F filing for Q4 2023, filed 15 Feb 2024.